


# Promising new treatment for dry eye disease

January 13 2022, by Michael Addelman



Link\_TSG6 suppresses CD3+ T cell infiltration in the lacrimal glands. A. Hematoxylin-eosin (H&E) staining of the extraorbital lacrimal glands in C57BL/6 control mice and NOD.B10.H2b mice receiving 7 days of PBS or Link\_TSG6 treatment (QID). Scale bar: 200 μm. B. CD3 immunostaining of the extraorbital lacrimal glands in C57BL/6 control mice and NOD.B10.H2b mice receiving PBS or Link\_TSG6 for 7 days (QID). Scale bar: 200 μm. C. Quantification of the number of inflammatory foci (an independent area of lymphocytic infiltration with >50 cells) in the extraorbital lacrimal glands. Each circle depicts the data from a single eye. Data (mean ± SD) were pooled from 3 independent experiments containing 3–5 animals per group in each experiment. \*\*p < 0.01, \*\*\*\*p

Citation: Promising new treatment for dry eye disease (2022, January 13) retrieved 27 April 2024 from <https://medicalxpress.com/news/2022-01-treatment-eye-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.